U.S., Sept. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07821762) titled 'A Study of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barre Syndrome' on Sept. 10.
Brief Summary: The main purpose of this study is to learn whether empasiprubart, when given in addition to intravenous immunoglobulin (IVIg), helps adults with Guillain-Barre syndrome (GBS) recover and whether it is safe. About 63 participants will be assigned by chance to receive either empasiprubart or placebo by intravenous infusion; all participants will also receive IVIg. The study includes screening for up to 72 hours, study treatment through Day 12, and follow-up through Week 67 (15 months after the last dose o...